<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

CU Cancer Center News and Stories


Alumni    Pediatric Cancer    Blood Cancer    Leukemia   

‘An Amazing Young Person’: A Teen’s Determination in Facing Leukemia Inspires a Bike Team in Children’s Hospital Colorado Fundraiser

A teenager’s leukemia struggle – and his mature attitude through his arduous treatment – impressed his University of Colorado Cancer Center medical team and spurred his mother to launch a foundation to raise money for cancer research. And now that struggle is providing inspiration for a cycling team as it prepares for the 2024 Courage Classic Bicycle Tour fundraiser for Children’s Hospital Colorado.

Author Mark Harden | Publish Date June 21, 2024
Full Story

Blood Cancer    Leukemia

Family Support and CU Cancer Center Treatment Helped Codie Mendez Survive Her Acute Lymphocytic Leukemia

It was time to move closer to family.

It was spring of 2020, and Codie Mendez was still grieving the loss of her brother, a California State Patrol officer who had been killed in the line of duty several months earlier. Adding to that the stress and the uncertainty of the rapidly developing COVID-19 pandemic, Codie and her husband, Mark, decided to move their family from Florida to Colorado to be closer to Mark’s parents. 

Things were supposed to be easier, more comfortable. 

But that wasn’t how it turned out.

Author Greg Glasgow | Publish Date June 18, 2024
Full Story

Patient Care    Blood Cancer    Leukemia

Football Coordinator With Leukemia Finds Winning Team at CU Cancer Center

Matt Lubick had finished marathons before, but none was so personally meaningful as the 26-mile distance he covered in one day while being treated for leukemia at UCHealth University of Colorado Hospital. Lubick walked dozens of laps around the facility, wheeling his IV pole up and down the corridors as day slowly turned to night outside the tall glass windows.

Author Greg Glasgow | Publish Date April 02, 2024
Full Story

Patient Care    Community    Leukemia   

Between a Rock and a Hard Place: Climber Tristan Chen Treated for Leukemia at CU Cancer Center

When your life is about being outdoors — about making your way up and around complex rock formations, looking for that flow you get into as every foothold and ledge reveals itself — the last place you want to be is stuck in a hospital bed, enduring the side effects of chemotherapy.

Author Greg Glasgow | Publish Date September 22, 2023
Full Story

Research    Leukemia

CU Cancer Center Research Finds the Pathway AML Cells Use to Avoid Therapeutic Elimination

New research conducted in the lab of University of Colorado Cancer Center co-deputy director James DeGregori, PhD, may explain why acute myeloid leukemia (AML) cells that reside in the bone marrow are more resistant to medication than AML cells found in the blood and elsewhere in the body.

Author Greg Glasgow | Publish Date November 11, 2022
Full Story

Community    Blood Cancer    Leukemia    Multiple Myeloma

The Latest on CAR T-Cell Therapy

September is Blood Cancer Awareness Month, a time for bringing attention to leukemia, lymphoma, myeloma, Hodgkin’s disease, and other blood cancers.

Author Greg Glasgow | Publish Date September 16, 2022
Full Story

Research    Pediatric Cancer    Blood Cancer    Leukemia    Clinical Trials

St. Baldrick’s Funds CU Study of New Pediatric Leukemia Drug 

As part of its ongoing efforts to eradicate childhood cancers, the St. Baldrick’s Foundation has awarded University of Colorado Cancer Center member Kelly Faulk, MD, a St. Baldrick’s Scholar grant to investigate a new method for treating infant leukemia

Author Greg Glasgow | Publish Date September 08, 2022
Full Story

Research    Blood Cancer    Leukemia

New Research Grant Underscores the CU Cancer Center’s Long Relationship With the Leukemia & Lymphoma Society 

In research that reinforces the University of Colorado Cancer Center’s longstanding relationship with the Leukemia & Lymphoma Society (LLS), CU Cancer Center member Lauren Nicholas, PhD, MPP, is co-principal investigator on a new LLS-funded study to examine the role of Medicare plan selection in dealing with a blood cancer diagnosis.  

Author Greg Glasgow | Publish Date August 30, 2022
Full Story

Community    Leukemia    Clinical Research    Drug Development

Presentation to Colorado Legislature Committee Will Highlight Breakthrough Research in Leukemia Treatment

University of Colorado (CU) Cancer Center researchers have been on the leading edge of developing new therapies for leukemia. One of the most recent breakthrough therapies has been the development of venetoclax, a B-cell lymphoma-2 inhibitor, that that has shown profound results for adults with acute myeloid leukemia (AML) and has become a standard of care for patients with this disease all over the world.

Author Rachel Sauer | Publish Date February 24, 2022
Full Story

Research    Pediatric Cancer    Leukemia

CU Cancer Center Member M. Eric Kohler, MD, PhD, Receives Award to Develop Immunotherapy Treatment for Pediatric Leukemia

University of Colorado Cancer Center member M. Eric Kohler, MD, PhD, was awarded a three-year, $270,650 Young Investigator Grant from CureSearch for Children’s Cancer, in partnership with the SebastianStrong Foundation, to develop a new treatment approach for acute myeloid leukemia (AML), a rare blood cancer in children.

Author Greg Glasgow | Publish Date September 17, 2021
Full Story

Blood Cancer    Leukemia

Norm MacDonald’s Death Puts Spotlight on Acute Leukemia

Comedian and former “Saturday Night Live” cast member Norm MacDonald died Tuesday, after what his brother, Neil MacDonald, described as a nine-year battle with acute leukemia. Norm MacDonald, known for his intelligence and sarcastic wit, was 61.

Author Greg Glasgow | Publish Date September 16, 2021
Full Story

Patient Care    Blood Cancer    Leukemia    Magazine    Clinical Trials

Acute Myeloid Leukemia (AML) Won’t Slow World Champion Triathlete Down

Siri Lindley couldn’t swim. She had never learned how and the idea of competing in a triathlon seemed completely out of the question.

Author Jessica Cordova | Publish Date May 16, 2021
Full Story

Research    Pediatric Cancer    Blood Cancer    Leukemia    Magazine

CU Cancer Center Researcher and Physician Poses Double Threat to Pediatric Cancer

M. Eric Kohler’s commitment to both cancer research — particularly CAR T-cell therapy — and clinical care make him a double threat when it comes to battling pediatric blood cancer.   

Author Valerie Gleaton | Publish Date March 26, 2021
Full Story

Research    Blood Cancer    Leukemia    Magazine

CU Cancer Center Leukemia Researcher Receives NCI Outstanding Investigator Award

Craig Jordan, PhD, has spent more than 20 years developing better treatments for acute myeloid leukemia (AML), a rapidly progressing cancer of the blood and bone marrow that can spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system.

Author Greg Glasgow | Publish Date November 23, 2020
Full Story

Research    Blood Cancer    Leukemia    Magazine

CU Cancer Center study leads to FDA approval of new treatment for AML

Thanks in large part to early work by investigators at the CU Cancer Center, patients with acute myeloid leukemia (AML) have a new treatment option that has fewer side effects and has been shown to increase longevity.

Author Cancer Center | Publish Date November 10, 2020
Full Story

Patient Care    Community    Faculty    Leukemia

Getting to the Root of Leukemia

The day before Joel Rutstein planned to leave for a week-long trip to Hawaii with his wife, Barbara, and their grown children, an oncologist in Fort Collins gave Joel bad news.

Author Garth Sundem | Publish Date January 03, 2019
Full Story

Patient Care    Leukemia    Clinical Trials

91 Percent Response Rate for Venetoclax Against Newly Diagnosed AML in Older Adults

Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. Of the three patients who did not respond to treatment, two discontinued the study before the first week due to personal reasons unrelated to treatment or side-effects.

Author Garth Sundem | Publish Date November 29, 2018
Full Story

Research    Leukemia    Cancer

Cancer Hijacks the Microbiome to Glut Itself on Glucose

Cancer needs energy to drive its out-of-control growth. It gets energy in the form of glucose, in fact consuming so much glucose that one method for imaging cancer simply looks for areas of extreme glucose consumption – where there is consumption, there is cancer. But how does cancer get this glucose? A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.

Author Garth Sundem | Publish Date September 28, 2018
Full Story

CU Cancer Center In the News


The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

news outletOncLive
Publish DateJuly 08, 2024

CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.

Full Story
News Medical

Study shows effectiveness of treating pancreatic cancer patients with chemotherapy before surgery

news outletNews Medical
Publish DateJune 19, 2024

A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.

Full Story
Cancer Network

Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups

news outletCancer Network
Publish DateJune 14, 2024

In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.

Full Story
Cancer Health

2024 Cancer Health 25: People Who Power Clinical Trials

news outletCancer Health
Publish DateJune 11, 2024

This year's Cancer Health 25 highlights the transformative power and promise of clinical trials. University of Colorado Cancer Center member Jessica McDermott, MD, MSCS, is leading clinical trials at both the CU Cancer Center and the Rocky Mountain Regional Veterans Affairs Medical Center. Additionally, she serves as the CU Cancer Center's deputy associate director for diversity and inclusion in clinical research.

Full Story